Drug Profile

FPI 2107

Alternative Names: [111In]-FPI-2107; FPI-2107

Latest Information Update: 21 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fusion Pharmaceuticals
Class Antineoplastics; Diagnostic agents; Indium radioisotopes; Radiopharmaceuticals
Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

13 May 2026 AstraZeneca terminates a phase I trial in Non small cell lung cancer (Diagnosis) in China (Parenteral) due to insufficient tumor uptake thought to be limited by the binding affinity of EGFR, the termination is not related to any safety or quality concerns (NCT07500987)
27 Feb 2026 Phase-I clinical trials in Non-small cell lung cancer (Diagnosis) in China (Parenteral) (NCT07500987)
04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com